<DOC>
	<DOCNO>NCT02669511</DOCNO>
	<brief_summary>An open-label , non-randomized , two-stage , multicenter study evaluate clinical efficacy , safety pharmacokinetics PQR309 patient relapse refractory PCNSL .</brief_summary>
	<brief_title>PQR309 Patients With Relapsed Refractory Primary CNS Lymphoma</brief_title>
	<detailed_description>An open-label , non-randomized , two-stage , multicenter study evaluate clinical efficacy , safety , pharmacokinetics effect PQR309 patient relapse refractory PCNSL . The first stage study enroll minimum 12 patient relapsed refractory PCNSL evaluable primary study objective . Following completion recruitment patient first stage study , decision make study team base continuous evaluation safety efficacy data , whether continue recruitment patient second stage await data analysis ( Nine ( 9 ) additional patient enrol second stage study , minimum 21 patient total , evaluable final primary endpoint analysis .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>≥18 year age . Patient histologically/cytologically confirm PCNSL Relapsed refractory PCNSL demonstrate cranial MRI . Presence least one lesion bidimensionally measurable disease baseline MRI contrastenhancing tumor least 1 cm ( 10 mm ) long diameter . Maximum one prior systemic therapy regimen . If receiving corticosteroid , patient must stable decrease dose corticosteroid 8 mg dexamethasone ( equivalent ) least 5 day prior date enrollment . Karnofsky Performance Score ( KPS ) ≥ 70 % . More 4 week investigational agent . Adequate haematological , liver renal function Able willing swallow retain oral medication . Female male patient reproductive potential must agree use effective contraception screen 90 day discontinue study treatment . Willing able sign inform consent comply protocol duration study . Secondary CNS lymphoma chronic immunosuppressionassociated CNS lymphoma . Previous allogeneic hematopoietic stem cell transplant ( HSCT transplant ) . Previous whole brain radiotherapy ( WBRT ) Other concomitant antitumor therapy determine study team . Patients unable undergo contrastenhanced MRI . Prior treatment PI3K inhibitor , AKT inhibitor , mTOR inhibitor . Patient take enzymeinducing antiepileptic drug ( EIAED ) &lt; 7 day first dose PQR309 . Patient take drug risk promote QT prolongation Torsades de Pointes . Patient currently use herbal preparation medication . Patient stop use herbal medication 7 day prior first dose study drug . Medically documented history active major depressive episode , bipolar disorder ( I II ) , obsessive compulsive disorder , schizophrenia , history suicidal attempt ideation , homicidal ideation ( e.g . risk harm self others ) , patient active severe personality disorder . Anxiety ≥CTC AE grade 3 . Patient uncontrolled intercurrent illness , Presence gastrointestinal disease condition could interfere significantly absorption study drug . Patient history invasive malignancy PCNSL . Women pregnant breast feeding . Women able conceive unwilling practice effective method birth control Fasting glucose &gt; 7.0 mmol/L ( 126 mg/dL ) HbA1c &gt; 6.4 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>